drugset / Trial / NCT01067859
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Timeline
- Start
- 2010-03
- Primary completion
- 2010-09
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinaciguat | Small molecule | 10 ug | Intravenous |
| Subject | Cinaciguat | Small molecule | 25 ug | Intravenous |